Ibrance (Palbociclib) 125 mg – Targeted Therapy for Breast Cancer Ibrance (Palbociclib)

Ibrance (Palbociclib) is an advanced targeted therapy used in the treatment of HR-positive / HER2-negative breast cancer. It is one of the first and most important CDK4/6 inhibitors that transformed the management of this disease.

What is Ibrance ?

Ibrance belongs to a class of drugs called CDK4/6 inhibitors, which regulate cell division.

In hormone receptor-positive breast cancer, these enzymes are overactive, leading to uncontrolled tumor growth. Ibrance works by:

• Blocking cancer cell division
• Slowing tumor progression
• Enhancing the effectiveness of hormonal therapy

In simple terms:
It shuts down the cancer cell’s division cycle.

Indications

Ibrance (Palbociclib) is used in:

• HR-positive breast cancer
• HER2-negative cases
• Advanced or metastatic disease
• In combination with hormonal therapy such as Letrozole or Fulvestrant

Dosage and Administration

• Standard dose: 125 mg once daily
• Taken orally
• Treatment cycle: 21 days on treatment + 7 days off
• Should be taken at the same time every day
• Dose adjustments may be required based on blood counts

Common Side Effects

May include:

• Low white blood cell count (neutropenia)
• Fatigue
• Nausea
• Loss of appetite
• Mild hair thinning
• Increased risk of infections

These side effects are usually manageable with proper monitoring.

Monitoring During Treatment

Patients on Ibrance require:

• Regular complete blood count (CBC)
• Symptom monitoring
• Ongoing assessment of treatment response

Availability in Egypt

Ibrance is available in specialized oncology centers and major pharmacies in Egypt.

• It is a high-cost medication
• Requires close supervision by an oncology specialist
• Used Within modern treatment protocols

Importance of Ibrance

Ibrance is a key advancement because it:

• Directly targets the cell cycle
• Significantly slows disease progression
• Improves outcomes when combined with hormonal therapy
• Is widely used in global breast cancer treatment guidelines

Ibrance (Palbociclib) Ibrance (Palbociclib) 125 mg is an effective targeted therapy for HR-positive / HER2-negative breast cancer, helping to control disease progression and improve patient outcomes in advanced stages.

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified oncology specialist.